Hormonal
Bariatric surgery (specifically Roux-en-Y gastric bypass and sleeve gastrectomy) is superior to behavioral and pharmacological interventions for long-term weight loss maintenance because it alters gut hormones and brain reward circuits, reducing compensatory hunger and metabolic adaptation.
Bariatric surgery is currently the most effective long-term intervention for obesity, largely because it biologically reduces hunger and alters food reward. However, it is not a permanent cure; significant weight regain can still occur. It should be viewed as a tool that facilitates weight loss, but long-term success still requires ongoing behavioral and nutritional support.
Bariatric surgery has, for a long time, been the most effective and durable means of weight loss... individuals who receive Roux-en-Y gastric bypass... consume 40% fewer calories and absorb 10% fewer calories from fat... patients... report a decrease in hunger and hedonic appeal of food.
Why this rating
Supported by multiple studies comparing surgery to behavioral/pharmacological interventions, though recent drugs are closing the gap.
Source
New insights in the mechanisms of weight‐loss maintenance: Summary from a Pennington symposium
Emily W. Flanagan et al. · Obesity · 2023
DOI 10.1002/oby.23905
More from this paper
- Long-term weight loss maintenance is physiologically opposed by metabolic adaptation (reduced energy expenditure) and hyperphagia (increased appetite), driven by neuroendocrine signals like leptin, making weight regain the default biological state.Strong
- Ultraprocessed foods contribute to weight regain and hinder weight loss maintenance by increasing caloric intake and body fat gain, independent of macronutrient composition, due to their palatability and marketing.Good
- Successful long-term weight loss maintenance is strongly predicted by high levels of physical activity (200-300 min/week) and behavioral strategies like self-monitoring, rather than just the amount of initial weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →